WNX Stock Chart & Stats
6.00 p
--
Market closed
6.00 p
--
Day’s Range― - ―
52-Week Range3.00 p - 14.10 p
Previous CloseN/A
VolumeN/A
Average Volume (3M)21.38K
Market Cap
£3.19M
Enterprise Value12.18 p
Total Cash (Recent Filing)£862.00K
Total Debt (Recent Filing)£9.68M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding73,026,810
10 Day Avg. Volume12,600
30 Day Avg. Volume21,378
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.06
P/FCF Ratio-0.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.65
Revenue Forecast (FY)£2.57B
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe rebound in revenue indicates improving scale and demand across Wellnex Life’s consumer healthcare activities. Sustained top-line expansion can broaden brand reach, support operating leverage, and provide a stronger foundation for margin recovery over the next several quarters.
Reduced LossesNarrowing losses show that the company is moving closer to breakeven despite remaining unprofitable. If this progress continues alongside revenue growth, Wellnex may improve capital efficiency and reduce the financial drag that currently limits reinvestment and strategic flexibility.
Balance-sheet RebuildingRebuilding equity from the highly stressed FY2023 position provides a more substantial capital base and indicates some balance-sheet repair. A stronger equity position can improve resilience and support business continuity while management works toward sustainable profitability and cash generation.
Bears Say
Gross-margin DeteriorationThe sharp gross-margin decline is a durable concern because it directly weakens the economics of each sale and makes break-even harder to reach. Unless pricing, product mix, or cost performance improves, revenue growth may not translate into operating profit or stronger cash generation.
Persistent Cash BurnNegative operating cash flow across every reported year shows that the business has not yet converted operations into self-funding cash generation. Continued cash consumption increases dependence on external funding and can constrain investment in brands, products, and distribution growth.
Higher Leverage While UnprofitableThe renewed increase in leverage is particularly concerning because Wellnex remains loss-making and cash-flow negative. Higher debt relative to equity can reduce financial flexibility, increase funding pressure, and limit management’s ability to absorb setbacks or finance growth internally.
Wellnex Life Ltd News
WNX FAQ
What was Wellnex Life Ltd’s price range in the past 12 months?
Wellnex Life Ltd lowest share price was 3.00 p and its highest was 14.10 p in the past 12 months.
What is Wellnex Life Ltd’s market cap?
Wellnex Life Ltd’s market cap is £3.19M.
When is Wellnex Life Ltd’s upcoming earnings report date?
Wellnex Life Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 178 days.
How were Wellnex Life Ltd’s earnings last quarter?
Wellnex Life Ltd released its earnings results on Aug 31, 2026. The company reported -0.02 p earnings per share for the quarter.
Is Wellnex Life Ltd overvalued?
According to Wall Street analysts Wellnex Life Ltd’s price is currently Overvalued.
Does Wellnex Life Ltd pay dividends?
Wellnex Life Ltd does not currently pay dividends.
What is Wellnex Life Ltd’s EPS estimate?
Wellnex Life Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Wellnex Life Ltd have?
Wellnex Life Ltd has 73,026,810 shares outstanding.
What happened to Wellnex Life Ltd’s price movement after its last earnings report?
Wellnex Life Ltd reported an EPS of -0.02 p in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wellnex Life Ltd?
Currently, no hedge funds are holding shares in GB:WNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wellnex Life Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Wellnex Life Ltd
Wellnex Life Limited, together with its subsidiaries, develops, markets, and sells health and wellness products in Australia, New Zealand, and the United Kingdom. The company offers topical anti-inflammatory creams, sprays, and roll-ons under the Pain Away brand; caffeine energy liquid capsules and multivitamins under the Wakey Wakey brand; sleep aid products under the Nighty Night brand; teeth whitening solutions under the Mr. Bright brand; pain relief capsules under the Wagner Liquigesics brand; medicinal cannabis under the Wellness Life brand; and over-the-counter medicines under the Pharmacy Own brand. It is also involved in the holding of intellectual properties and trademarks of its products; brand and pharma solution businesses; and investment activities. The company was formerly known as Wattle Health Australia Limited and changed its name to Wellnex Life Limited in June 2021. Wellnex Life Limited was incorporated in 2011 and is headquartered in Port Melbourne, Australia.
Technical Analysis
―
Bubs Australia Ltd.
―
Nuchev Pty Ltd
―
Holista Colltech Limited
―
Nutritional Growth Solutions Ltd.
―